Phaxiam Therapeutics SA (PXMTF)
OTC PINK OTC PINK Primary Summary
Phaxiam Therapeutics SA (PXMTF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Phaxiam Therapeutics SA ever had a stock split?
Phaxiam Therapeutics SA Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jérôme Bailly Pharm.D. CEO | OTC PINK Exchange | - ISIN |
| France Country | 68 Employees | - Last Dividend | 18 Sep 2023 Last Split | - IPO Date |
Overview
PHAXIAM Therapeutics S.A. is a dynamic force in the biopharmaceutical sector, with a focus on developing innovative treatments for resistant bacterial infections. Operating both in France and the United States, the company represents a pivotal player in the quest against some of the most challenging medical concerns of our time. Initially known as ERYTECH Pharma S.A., it underwent a strategic rebranding to PHAXIAM Therapeutics S.A. in June 2023, marking a new chapter in its mission. Founded in 2004 and headquartered in Lyon, France, PHAXIAM Therapeutics S.A. is committed to leveraging cutting-edge science to improve patient outcomes in areas where traditional treatments no longer suffice.
Products and Services
- Eryaspase
At the forefront of PHAXIAM Therapeutics’ innovation pipeline is eryaspase, a pioneering therapeutic solution currently undergoing rigorous clinical evaluation. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, demonstrating PHAXIAM Therapeutics’ commitment to addressing hard-to-treat cancers. Additionally, eryaspase is being explored in Phase 2 clinical trials for its potential in treating triple-negative breast cancer and second-line acute lymphoblastic leukemia patients, showcasing the drug's versatility and the company's dedication to expanding its therapeutic applications.
- Phage Portfolio
Understanding the critical challenge posed by antibiotic-resistant bacteria, PHAXIAM Therapeutics is also engaged in the development of a comprehensive portfolio of bacteriophages. These phages are specifically targeted at combating resistant and hazardous bacteria responsible for over two-thirds of resistant hospital-acquired infections. The focus includes notorious pathogens such as staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. This cutting-edge approach reflects PHAXIAM Therapeutics’ broader vision of employing novel biotechnologies to confront and overcome some of the most pressing healthcare dilemmas of our era.
